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Abstract
Purpose Panobinostat is partly metabolized by CYP3A4
in vitro. This study evaluated the effect of a potent CYP3A
inhibitor, ketoconazole, on the pharmacokinetics and safety
of panobinostat.
Methods Patients received a single panobinostat oral dose
on day 1, followed by 4 days wash-out period. On days 5–
9, ketoconazole was administered. On day 8, a single
panobinostat dose was co-administered with ketoconazole.
Panobinostat was administered as single agent three times a
week on day 15 and onward.
Results In the presence of ketoconazole, there was 1.6-
and 1.8-fold increase in Cmax and AUC of panobinostat,
respectively. No substantial change in Tmax or half-life was
observed. No difference in panobinostat-pharmacokinetics
between patients carrying CYP3A5*1/*3 and CYP3A5*3/
*3 alleles was observed. Most frequently reported adverse
events were gastrointestinal related. Patients had asymp-
tomatic hypophosphatemia (64%), and urine analysis sug-
gested renal phosphate wasting.
Conclusions Co-administration of panobinostat with
CYP3A inhibitors is feasible as the observed increase in
panobinostat PK parameters was not considered clinically
relevant. Considering the variability in exposure following
enzyme inhibition and the fact that chronic dosing of
panobinostat was not studied with CYP3A inhibitors, close
monitoring of panobinostat-related adverse events is
necessary.
Keywords Panobinostat   LBH589   Histone deacetylase
inhibitor   CYP3A
Introduction
Histone deacetylases (HDACs) are enzymes controlling the
acetylation state of lysine protein residues, notably those
contained in the N-terminal portions of the core histones,
and are functionally counteracted by histone acetylases.
The balance between these two enzyme groups controls
cell cycle progression, cell survival and differentiation. In
neoplastic cells, the abundance of deacetylated histones is
usually associated with DNA hypermethylation and gene
silencing [1, 2]. As a new class of chemotherapeutic agents,
HDAC inhibitors (HDACi) have demonstrated potent
anticancer activities in preclinical studies and are currently
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basis of the anticancer effects of HDACi goes beyond the
inhibition of histone acetylation alone. Over the last several
years, a growing list of non-histone targets important in the
regulation of cell proliferation, cell death and cell migra-
tion have been identiﬁed, including p53, NF-jB, Ku70,
a-tubulin and Hsp90 [3].
HDACs are grouped based on their catalytic mecha-
nism: class 1 (HDACs 1,2,3 and 8), class II a/b (HDACs
4,5,6,7,9 and 10), class III (sirtuin enzymes) and Class IV
(HDAC 11) [2]. Inhibitors of HDAC class I as well as class
II are arbitrarily called pan-deacetylase inhibitors (pan-
DACi).
Panobinostat (LBH589) is a pan-DACi, which belongs
to a structurally novel cinnamic hydroxamic acid class of
compounds [4].
It is one of the most potent class I/II pan-DACi in vitro
and has shown antitumor activity in a wide variety of tumor
xenograft models. Reports from phases I–II studies have
demonstrated signs of clinical activity of panobinostat in
patients with cancer, e.g., in cutaneous T-cell lymphoma,
Hodgkin’s or non-Hodgkin’s lymphoma, prostate cancer,
acute myeloid leukemia, multiple myeloma and breast
cancer [5–7]. Phase II studies are ongoing in patients with
hematological malignancies and solid tumors. Thrombo-
cytopenia and fatigue were the dose-limiting toxicities in
the phase I study after oral administration of panobinostat.
Other major toxicities were nausea and vomiting.
Panobinostat is metabolized via multiple pathways
including reduction, hydrolysis, oxidation and glucuroni-
dation. The oxidative metabolism of panobinostat is med-
iated mainly by human cytochrome P450 CYP3A4 (70–
98%) with minor involvement of CYP2D6 and CYP2C19.
CYP3A is a predominant family of CYP enzymes,
which makes it one of the most important drug-metabo-
lizing enzymes. CYP3A is expressed primarily in liver and
small intestine [8]. Since hepatic CYP3A4 has been esti-
mated to metabolize close to 50% of currently used drugs,
as well as endogenous and exogenous steroids, it is evident
that anticancer agents including panobinostat given in
combination with drugs that are CYP3A4 inhibitors are
likely to result in clinical toxicity. Indeed, based on in
silico drug–drug interaction (DDI) modeling and simula-
tion, ketoconazole, a strong CYP3A4 inhibitor, was pre-
dicted to increase panobinostat AUC by 1.3–2 fold. Thus, a
decision was made to study panobinostat at the lowest
efﬁcacious dose at 20 mg/day to assess the clinical drug–
drug interaction potential. The study was designed to
determine the effect of a strong CYP3A inhibitor on the
systemic exposure to panobinostat, in order to assess
whether or not co-administration with a CYP3A inhibitor
can be allowed in patients if medically necessary during
treatment with panobinostat.
The primary and secondary objectives of this study were
to investigate the effect of multiple doses of ketoconazole
on the pharmacokinetics of a single dose of panobinostat
and safety, respectively.
Patients and methods
Patient selection
Patient selection was performed at the phase I outpatient
department. Patients with histologically or cytologically
conﬁrmed advanced or metastatic solid tumors for whom
no standard therapy was available and with an Eastern
Cooperative Oncology Group (ECOG) performance status
B2 were eligible. Since clinical responses were observed in
phase I/II trials with panobinostat, the selection of this
phase I patients population with no other therapeutic
options was considered appropriate for this study where a
prolonged treatment with a potentially active drug was
offered to these patients, although, based on tumor char-
acteristics no potential beneﬁt was anticipated beforehand.
The serum potassium, total corrected calcium, magnesium
and phosphorus had to be above the lower limit of normal.
QTc had to be B450 ms. Concomitant treatment with
CYP3A inhibitors and medications which increase the risk
of Torsades de Point was not allowed. Signiﬁcant cardiac
disease or other concurrent uncontrolled medical conditions
were exclusionary criteria. The study was designed and
conductedundertheappropriateinstitutionalreviewboards’
approvalsandinaccordancewiththeprinciplesembodiedin
the Declaration of Helsinki. Written informed consent was
obtained from each participant. This study is registered as
NCT00503451 (http://www.ClinicalTrials.gov).
Study design
Patients received single-agent panobinostat at 20 mg orally
after at least 2 h fasting on day 1 and single-agent keto-
conazole once daily at 400 mg on days 5–9 (Fig. 1). On
day 8, panobinostat was administered 1 h after ketocona-
zole. If at interim analysis after evaluation of 12 patients
any of the four parameters (AUC0–24, AUC0–tlast, AUC0–?
and Cmax) had the paired t statistic (calculated based
on log-transformed data) falling outside of (-1.98405,
1.98405), then the recruitment was to be stopped. If not, the
trial was to proceed until 16 patients completed the study.
The study design also stipulated that, while completer
status for 12 patients was being conﬁrmed, enrollment was
not halted as long as there were no safety concerns.
All patients enrolled before this interim analysis were to
proceed to the extension phase regardless of the interim
result. From day 15 onward, the extension phase of the
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123study started in which patients received single-agent 20 mg
oral panobinostat each Monday, Wednesday and Friday
(MWF) until disease progression, patient withdrawal of
consent or unacceptable toxicity. Toxicity was evaluated
using the Common Terminology Criteria for Adverse
Events (CTCAE) v 3.0.
Safety assessments
Close monitoring by evaluating signs and symptoms,
physical examination, laboratory assessments and ECGs
was performed during the trial. Patients had scheduled
visits on days 1, 2, 3, 5, 8, 9, 10 and 15. Laboratory
assessments were scheduled at days 1, 5, 8, 9, 10 and 15.
Twelve-lead ECGs were scheduled as follows: predose day
1 and at 1.5, 3, 6, 24 and 48 h post-dose; preketoconazole
dose on day 5 and at 1.5 and 3 h post-dose; preketoco-
nazole on day 8 and 1.5, 3, 6, 24 and 48 h post-dose
panobinostat; and predose on day 15. All ECGs were taken
at least in triplicate separated by 2–5 min and were
reviewed independently at a central laboratory (eRT,
Bridgewater, NJ). During the extension phase, single ECGs
were performed weekly as were laboratory assessments.
Bazett’s formula was used to correct QT intervals for heart
rate.
Pharmacokinetic evaluation
During cycle 1 at days 1 and 8, patients had serial blood
sampling collections for pharmacokinetic evaluation of
panobinostat. Blood samples (3 ml/sample) were collected
in tubes containing sodium heparin prior to panobinostat
dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 24 and 48 h post-
dose. Samples were centrifuged at 800 g for 15 min at 4C
to yield plasma within 60 min after blood collection and
stored below -60C until analyses.
Blood samples (3 ml) for ketoconazole concentration
determinations were collected predose and 2 h post-dose of
ketoconazole on days 5, 8 and 9 (Fig. 1).
Panobinostat is analyzed in human plasma samples
using a speciﬁc LC–MS/MS method with the lower limit of
quantiﬁcation (LLOQ) of 0.5 ng/ml and a dynamic range
of 0.5–500 ng/ml of the analyte using 0.1 ml sample vol-
ume. A semi-automated protein precipitation extraction of
human plasma samples was used to separate panobinostat
from human plasma protein. The obtained sample extracts
were evaporated to dryness, reconstituted with 10% aque-
ous acetonitrile (containing 0.2% formic acid) and ana-
lyzed by LC–MS/MS on a Sciex API3000 or a Sciex
API4000 tandem mass spectrometer. A Waters Xbridge
C8 column (2.5 lm particle size, 50 9 2.1 mm) was
employed in reversed-phase chromatography with gradient
elution using 10% acetonitrile in water (containing 0.1%
formic acid and 0.1% acetic acid, mobile phase A) and
90% acetonitrile in water (containing 0.25% formic acid
and 0.25% acetic acid, mobile phase B) at a ﬂow rate of
0.3 ml:/min. The assay was linear from 0.5 to 500 ng/ml
with the bias (%) and CV(%) values of the QC sample
results ranging from -0.7 to 0.7% and 2.3 to 11.6%,
respectively, based on the within-study validation during
the sample analysis.
For determination of ketoconazole in human plasma, a
100 ll aliquot of each sample (Standards, QC samples,
study samples, blanks, etc.,) was pipetted into the appro-
priate well in a 96-deep-well plate. A 100 ll aliquot of the
internal standard working solution (250 ng/ml in 50%
acetonitrile, v/v) was added to all wells except for the
blanks, to which a 100 ll aliquot of 50% acetonitrile was
Fig. 1 Study design. Time points of dosing and pharmacokinetic sampling
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123added. A 400 ll aliquot of acetonitrile was added to each
well, the plate covered, vortexed for approximately 10 min
and centrifuged at approximately 4,000 rpm for approxi-
mately 10 min at room temperature. Using a TomTec
device, a 50 ll aliquot of sample extract was transferred to
a clean 96-deep-well plate, followed by an addition of
450 ll of 30% acetonitrile in water (v/v). After a brief
vortex mixing, a 10 ll aliquot was injected onto the HPLC
system connected to a Sciex API5000 mass spectrometer.
The assay was linear from 50.0 to 15,000 ng/ml with the
bias (%) and CV(%) values of the QC sample results
ranging from -4.2 to 3.3% and 6.0 to 8.6%, respectively,
based on the within-study validation during the sample
analysis.
Panobinostat plasma concentration–time curve follow-
ing each dose from individual patient was used to calculate
pharmacokinetic parameters that included Cmax, Tmax and
AUC0–?. PK parameters were obtained using non-com-
partmental methods implemented in WinNonlin Pro soft-
ware (Version 5.01, Pharsight Corporation, Mountain
View, CA, USA). Cmax and Tmax were obtained by visual
inspection of the concentration–time curve. AUC0–? was
calculated using the linear up/log down method up to the
last measured concentrations and the additional area esti-
mated from that concentration and the value of apparent
terminal half-life estimated for the targeted administration.
The apparent terminal half-life was estimated using the
best-ﬁt variables of a single exponential to the log-linear
portion of the plasma concentration–time curve using non-
weighted linear regression.
Ratio was calculated using the following formula: ð½PK-
parameter panobinostatþketoconazole=½PK-parameter panobinostatÞ.
Pharmacogenetic evaluation
Blood samples (1.5 ml in EDTA-containing tubes) were
obtained at baseline for genotyping analysis of
CYP3A4*1B, CYP3A5*2, *3, *6 and *7 and performed
using AmpliChip CYP450 at Epidauros, Bernried, Ger-
many. DNA preparation and sequencing followed the
method described by Sanger et al. (16), using commercial
kits provided by Applied Biosystems. Wild-type allele
CYP3A4*1A is deﬁned as the exclusion of allele
CYP3A4*1B. Wild-type allele CYP3A5*1 is deﬁned as the
exclusion of alleles *2, *3, *6 and *7.
Sample size calculation and statistical considerations
Pharmacokinetic evaluations to determine the inﬂuence of
the potent CYP3A inhibitor ketoconazole on the pharma-
cokinetics of panobinostat were conducted during cycle 1 at
days1–14.Asamplesizeof16wouldhaveprovidedenough
power (82.4%) to detect a minimum increase of 30%
(ketoconazole plus panobinostat vs. panobinostat alone)
with an alpha level of 0.1. Since strong interaction between
ketoconazole and panobinostat is possible, a ratio higher
than 1.3 (ketoconazole plus panobinostat vs panobinostat
alone) might be observed. Thus, a drug–drug interaction
(DDI) could become apparent with fewer patients, and
stopping if this occurs avoids unnecessary exposure of
patientstostudymedications.AninterimanalysisofPKdata
was carried out when 75% of anticipated patients (12 com-
pleted patients out of 16 planned completers) were enrolled
and had completed the core phase.
The number of 12 patients was chosen with two con-
siderations. A sample size of 12 is generally accepted to
evaluate safety [9], and secondly, it provided reasonable
power for stopping at interim. The O’Brien–Fleming
method was used to calculate the boundaries at interim and
ﬁnal analyses [10].
A linear mixed effects model was ﬁt to the log-trans-
formed PK parameters (Cmax and AUC0–24, AUC0–t and
AUC0–?). Included in the model was treatment (ketocona-
zole ? panobinostat or panobinostat alone) as ﬁxed effects
and patient as a random effect. For the DDI analysis, the
combination treatment (ketoconazole ? panobinostat) was
the test and panobinostat alone the reference. Proper con-
trasts were used to estimate the treatment difference (i.e.,
ketoconazole ? panobinostat vs. panobinostat alone). The
point estimate of the treatment difference and the corre-
sponding 90% conﬁdence intervals were calculated and
back-transformed to obtain the point estimate and CI on the
linear scale for the ratio of geometric means of the test as
compared with the reference. The median, minimum and
maximum of Tmax difference between test and reference
were also presented.
Results
The interim analysis resulted in early stop of the study.
Fourteen patients were enrolled, all of them evaluable for
pharmacokinetic and safety assessment. Thirteen patients
continued in the extension phase. One patient discontinued
the study in the core phase due to mild increase in serum
creatinine. Patient characteristics are shown in Table 1. All
14 patients have discontinued the study (10 for disease
progression, three for adverse events, one for on-treatment
death unrelated to study drug due to myocardial infarction).
The mean duration of exposure to panobinostat was
140 days (median [range]: 59 [8, 899] days).
Pharmacokinetic evaluation
Pharmacokinetic parameters are shown in Table 2.N o
residual panobinostat was detectable prior to the day 8 dose
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zole). In the presence of ketoconazole, peak plasma con-
centration of panobinostat (Cmax) increased from 18.52 to
29.98 ng/ml, and the area-under-the-curve0–? (AUC0–?)
rose from 133 to 220.7 ng h/ml, generating ratios of 1.6
(90% CI 1.2–2.2) and 1.8 (90% CI 1.5–2.2), respectively.
No substantial change in time to maximum concentration
(Tmax) or half-life was observed. Individual geometric
mean ratios of panobinostat Cmax and AUC are shown in
Fig. 2. Of note, in a limited number of patients, a higher
than twofold increase in Cmax and AUC of panobinostat
was observed in the presence of ketoconazole.
Pharmacogenetic evaluation
Genotype analysis of CYP3A4*1B, CYP3A5*2, *3, *6
and *7 was performed and available at baseline from all
14 patients. All patients in this study were Caucasians.
Fourteen patients were homozygous for the wild-type
CYP3A4*1A genotype. Eleven patients were homozygous
for the CYP3A5*3 genotype, and 3 patients were hetero-
zygous for the CYP3A5*1/*3 genotype.
There is no apparent difference in panobinostat Cmax or
AUC value between patients carrying CYP3A5*1/*3 and
CYP3A5*3/*3 alleles.
Table 1 Demographics, tumor types and prior treatment
Age, median (range) in years 59 (41–74)
Male 9 (64%)
Female 5 (36%)
Caucasian 14 (100%)
ECOG PS
0 3 (29%)
1 9 (57%)
2 2 (14%)
Primary tumor
Colorectal 3 (21%)
Pancreas 2 (14%)
Breast 1 (7%)
Prostate 1 (7%)
Salivary gland 1 (7%)
Thyroid 1 (7%)
Head and neck 1 (7%)
Other primary tumor sites 4 (29%)
Prior antineoplastic systemic
treatment
Yes 12 (86%); Range (1–8 regimens)
No 2 (14%)
Prior radiotherapy
Yes 9 (64%)
No 5 (36%)
Table 2 Analysis of pharmacokinetic parameters of panobinostat administered alone or concomitantly with ketoconazole
Pharmacokinetic parameter (unit) Panobinostat alone
(n = 14)
a
Panobinostat ? ketoconazole
(n = 14)
a
Ratio (90% CI)
b
Cmax (ng/ml) 18.52 (42.6) 29.98 (93.3) 1.6 (1.2–2.2)
AUC0–? (ng h/ml) 133.0 (39.9)
c 220.7 (54.6)
d 1.8 (1.5–2.2)
Tmax (h) 1.00 (0.5–4.0) 1.00 (0.5–6.0) 0.0 (-2.5 to 3.0)
T1/2 (h) 14.0 (6.5–17.2)
c 13.4 (7.2–20.9)
d
CL/F (L/h) 150.3 90.6
a Values are median (range) for Tmax and T1/2 and geometric mean (CV%) for all other parameters
b Statistical analysis performed on the primary endpoint pharmacokinetic parameters to show geometric mean ratios for Cmax and AUC0–? and
median (minimum and maximum difference) for Tmax
c Data available on n = 11
d Data available on n = 12
Fig. 2 Individual patient panobinostat PK parameters ratios (pano-
binostat ? ketaconazole/panobinostat) and geometric mean ratio
(GMR; value as represented by vertical line) with 90% CI (bars)
Cancer Chemother Pharmacol (2011) 68:805–813 809
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In order to determine whether the combination of panobi-
nostat plus ketoconazole resulted in additional toxicity, the
core phase of the study was subdivided into 3 parts: period
1 from day 1 until the ﬁrst dose of ketoconazole (on day 5);
period 2 from ﬁrst dose of ketoconazole until concomitant
administration of panobinostat with ketoconazole (on day
8) and period 3 from the time point of this combination
until day 15.
Most patients (12/14 patients, 85.5%) had at least one
adverse event during the core phase of the study. Overall,
the most frequently reported AEs regardless of relationship
to study drug were diarrhea (reported in 5 patients), anor-
exia (4) vomiting (4), nausea (3), hypophosphatemia (3),
myalgia (3) and fatigue (2). The majority of the AEs were
categorized as grade 1 or grade 2 (42.9 and 35.7% of all
events, respectively).
No relevant difference was seen in ECG readings across
the three periods in the core phase. The highest incidence
of QTc prolongation[30 ms (ms) as compared with
baseline was observed in 5 patients (36%) in period 3
(concomitant panobinostat and ketoconazole), while this
increase was seen in 4 patients (29%) and 3 patients (21%)
in periods 1 (panobinostat only) and 2 (ketoconazole only),
respectively. No increases in QTc C 60 ms compared with
baseline were observed. In six patients (43%), other tran-
sient ECG abnormalities were detected during period 3,
while these were seen in 3 (21%) patients in either period 1
or 2 (Table 3).
One possibly study drug-related serious adverse event
occurred during the core phase of the study. On day 7, after
commencing study drug, a patient developed a mild
increase in his serum creatinine level from 1.09 mg/dl at
baseline to a maximum of 1.72 mg/dl. His concomitant
medications were doxazosin, irbesartan and hydrochloro-
thiazide for preexistent hypertension. His creatinine level
returned to baseline after discontinuing the diuretic. Study
treatment was permanently discontinued due to this
adverse event. Overall, no differences were observed
among periods 1, 2 and 3 of the core phase of the trial.
Adverse events were reported in all 13 patients
continuing in the extension phase. Similar safety proﬁle
was seen in the extension phase of the study, the most
frequently reported AEs regardless of relationship to study
drug were nausea (reported in 10 patients), hypophos-
phatemia (9), diarrhea (8), vomiting (8), fatigue (7),
anorexia (7), whereas thrombocytopenia was only noted in
the extension phase in four patients, most likely due to
longer treatment duration and corresponding higher
exposure in the extension phase. The spectrum of adverse
events reported in this trial was comparable with the
toxicity pattern from the previous trials with panobinostat
[5, 6, 11, 12]. Asymptomatic hypophosphatemia of gra-
de C 2 occurred in a total of nine out of fourteen patients
(64%) during the trial. In two of these patients, hypo-
phosphatemia grade 2 was present before start of treat-
ment; two other patients showed it on day 5 in the core
phase, before starting ketoconazole. To further explore this
ﬁnding, ad hoc urine analysis to measure fractional
excretion of phosphate was performed in three out of the
seven patients with treatment-emergent hypophosphatemia
(6 samples) during the extension phase.
The fractional excretion of phosphate ranged from 2.7 to
19.4%, while the fractional excretion of phosphate excee-
ded 5% in all these patients in at least one sample (in total 4
out of 6 samples) (Table 4). No baseline samples were
available.
Table 3 ECG changes during the core phase of the trial
Period 1
a Period 2
a Period 3
a
QTcB increase[30 ms 4 (29%) 3 (21%) 5 (36%)
QTcB increase[60 ms 0 0 0
New QTcB[450 ms 3 (21%) 2 (14%) 2 (14%)
Sinus bradycardia 0 1 (7%) 0
Sinus tachycardia 0 0 2 (14%)
ST segment depression 0 0 2 (14%)
T wave changes 2 (14%) 1 (7%) 2 (14%)
Ectopic activity 2 (14%) 1 (7%) 2 (14%)
In all rows, the number of patients is given (the percentage of patients
between brackets; N = 14 in all periods)
a Period 1 from day 1 until the ﬁrst dose of ketoconazole; period 2
from ﬁrst dose of ketoconazole until concomitant administration of
panobinostat with ketoconazole (on day 8); and period 3 from the
time point of this combination until day 15
Table 4 Fractional excretion of phosphate in patients reporting hypophosphatemia in the extension phase based on ad hoc urine analysis
Gender, age, tumor diagnosis Fractional excretion
of phosphate in % (study day)
Fractional excretion
of phosphate in % (study day)
Subj nr 00010 Female, 55 years, invasive ductal carcinoma of the breast 2.7 (day 36) 8.9 (day 43)
Subj nr 00005 Female, 50 years, rectal adenocarcinoma 5.3 (day 54) 3.2 (day 61)
Subj nr 00007 Male, 71 years, cystic adenoid head and neck carcinoma 19.4 (day 70) 19.0 (day 77)
Fractional excretion of phosphate: Phosphate ½  urine   Creatinine ½  plasma  100
no .
Phosphate ½  plasma  Creatinine ½  urine
no
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Disease stabilization for at least 3 months was achieved in
37.5% of the patients with two patients (adenoid cystic
carcinoma of head and neck, and salivary gland) staying on
study treatment for 333 and 899 days, respectively.
Discussion
The prevalence of polypharmacy is increasing and is an
important issue with regard to potential drug–drug inter-
actions with untoward consequences. This study aimed to
determine whether co-administration of a strong CYP3A
inhibitor in patients treated with panobinostat would result
in a clinically relevant change in the exposure after a single
dose of panobinostat. Emerging results from this DDI study
with ketoconazole and a radiolabeled mass balance study
[7] have shed light on potential drug–drug interaction risk
with respect to panobinostat as a CYP3A substrate. Only a
limited increase in Cmax and AUC of panobinostat was seen
in most of the patients, with a ratio of 1.6 and 1.8 in the
presence of ketoconazole, respectively, without a change in
Tmax or half-life. In the two dose-escalation trials, these two
pharmacokinetic parameters have shown to increase line-
arly with the dose between 20 and\60 mg [6, 13].
A comparison of the metabolites observed in vivo with
those formed in human liver in vitro and by recombinant
cytochrome P450 (CYP) enzymes indicated that the con-
tribution of oxidative metabolism pathways mediated by
CYP enzymes in patients was less than the contributions by
other panobinostat metabolic pathways (e.g., reduction,
hydrolysis, 1- and 2-carbon chain shortening and glucu-
ronidation) (personal communications with Heidi Einolf,
Novartis). Therefore, the impact of clinical drug–drug
interactions via CYP enzymes was predicted to be minor.
This was conﬁrmed in the present study showing a\two-
fold increase in panobinostat AUC following consecutive
doses of ketoconazole at 400 mg. As the AUCinhibition/AUC
ratio was 1.8, the fmCYP3A (fraction of panobinostat cleared
by CYP3A) was estimated to be 0.4 using the following
formula [AUCinhibition/AUC = 1/(1 - fmCYP3A)] [14]
indicating CYP pathways contributed\50% to the overall
metabolism of panobinostat.
In this study, the genotype status of CYP3A does not
seem to be of relevance as there was no apparent difference
in panobinostat levels in patients harboring CYP3A5*1/*3
compared with those with CYP3A5*3/*3 alleles. However,
no conclusions can be drawn with respect to CYP3A4 as
only patients with homozygous wild-type CYP3A4*1A
genotype were enrolled in this trial.
The impact of inter-individual (60%) and intra-individ-
ual (30%) variabilities (personal communication Margaret
M Woo, Novartis) in the pharmacokinetics of panobinostat
is larger than the effect of CYP3A inhibitors (Table 2),
rendering individual titration of the panobinostat dose,
based on the observed toxicity during treatment, of far
greater relevance than the concomitant use of a CYP3A
inhibitor. Close monitoring of patients would be recom-
mended whenever chronic co-administration of a potent
CYP3A4 inhibitor is unavoidable during treatment with
panobinostat.
It is worth noting that although, the recommended phase
II dose in patients with solid tumors is set at 20 mg MWF
each week, the increase in Cmax and AUC of panobinostat
in the presence of ketoconazole at this dose should be put
in perspective as higher doses of 40 and 60 mg are given
MWF every week in patients with Hodgkin’s lymphoma
and acute myeloid leukemia, respectively [6, 12]. How-
ever, we should be cognizant that severe thrombocytopenia
in patients with solid tumors is regarded as a DLT, whereas
this is not necessarily the case in patients with acute
myeloid leukemia due to the underlying disease. Throm-
bocytopenia was the most common grade 3/4 toxicity,
occurring in 10 out of 13 patients during dose escalation, in
patients with Hodgkin’s lymphoma and was dose limiting
in four of them [12].
Clinical evaluation in the core phase of this study was
short (15 days), but no unexpected toxicity was observed
due to a potential interaction between panobinostat and
ketoconazole. Thrombocytopenia was present in the
extension phase, when repeated doses of panobinostat
20 mg MWF were administered, but overall the safety
proﬁle remained as expected.
QTc prolongation has drawn attention during a phase I
study with continuous intravenous administration of pan-
obinostat [12]; however, in our current study as well as in
the other studies using oral panobinostat, this does not
seem to be a major issue [5, 6, 11, 12]. At least at 14 time
points during the 15 days of the core phase of this study,
ECGs were procured in order to obtain more data on a
potential QTc prolongation. The mean increase at any
moment during the core phase compared with baseline was
below 5%. Also during the extension phase, the only
observed QTc abnormalities were increases in QTc larger
than 30 and B60 ms.
The occurrence of hypophosphatemia during treatment
with HDAC inhibitors has been previously described [15–
17], and a recent review of toxicities reported with HDAC
inhibitors mentions asymptomatic hypophosphatemia as
one of the common AEs reported in single-agent vorinostat
(5%), romidepsin (8%) and entinostat (29%) [16].
As mildasymptomatic hypophosphatemiawasalso noted
in this study, and in order to evaluate renal phosphate
wasting, ad hoc urine analysis was performed during the
extension phase and the ﬁndings were suggestive of renal
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fractional excretion of phosphate[5%. Due to lack of pre-
deﬁned baseline and serial assessments of phosphate in
urine,ﬁrmconclusionscannotbedrawnfromthisunplanned
and explorative analysis, which should be regarded as
hypothesis generating. Given the occurrence of hypophos-
phatemia was observed during panobinostat treatment
before the initiation as well as after discontinuing of keto-
conazole treatment, it seems unlikely that hypophosphate-
miaiscausedbyco-administrationofaCYP3Ainhibitor.At
present,theexactmechanismofthissideeffectisnotknown
and should deserve further studies focusing on potential
tubular toxicity as a result of DAC inhibition, as hypo-
phosphatemia might be a class effect of DAC inhibitors.
In our study, patients were monitored for electrolyte
serum levels and received electrolyte supplements as soon
as an electrolyte deﬁcit was noted. Similar management of
asymptomatic hypophosphatemia was successfully repor-
ted in a study with MS-275, a benzamide derivative, in
patients with solid tumors and lymphoma [17].
As drug–drug interactions become more and more
important in the era of personalized medicine, the extent of
potential interactions should be explored in the early phase
of drug development. In this study, in which each patient
served as their own control, a weak interaction was found
between the pan-DAC inhibitor panobinostat and the
CYP3A inhibitor ketoconazole. Because the interaction is
weak, it may not be clinically relevant. In our opinion, the
observed toxicity is not attributable speciﬁcally due to
concurrent CYP3A inhibtion because a similar safety pat-
tern was reported for the drug interaction in the evaluation
phase and as a single agent in the extension phases of the
study. Most patients reported gastrointestinal-related
events as well as metabolism and nutrition disorders, and
most adverse events were of either grade 1 or 2. Throm-
bocytopenia was observed in 4 patients and neutropenia in
2 patients, when panobinostat was administered for a pro-
longed period of time, but not when administered with
ketoconazole. However, the interpretation of the results
should be taken with caution due to the variable treatment
in each individual and observation duration in the exten-
sion phase.
Conclusion
Concomitant treatment with a strong CYP3A inhibitor
increased Cmax and AUC of panobinostat by 1.6- and 1.8-
fold, respectively. Close monitoring of patients would be
recommended whenever chronic co-administration of a
strong CYP3A4 inhibitor is unavoidable during treatment
with panobinostat. Asymptomatic hypophosphatemia has
been observed and might be a result of renal phosphate
wasting; whether this is a HDACi class effect should be
further explored.
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